Buenavista Equity Partners has officially launched the BV Healthcare Growth Innvierte I fund, securing an initial closing of €100 million, with a target size of €150 million.

A significant boost to the fund comes from Spain's Centre for Technological Development and Innovation (CDTI), which has committed up to €58 million through its Innvierte Programme.

This fund is a collaboration with Columbus Venture Partners, combining the expertise of both firms in private equity and venture capital to focus on healthcare investments.

Damià Tormo from Columbus emphasized the fund’s strategy to address the financing gap for high-growth medical companies in Spain and Europe, particularly in the absence of specialized investor support.

The fund aims to invest in 10 to 12 innovative healthcare companies, primarily in Spain, with individual investments reaching up to €15 million.

Nuria Osés, a partner at Buenavista, noted that the fund is dedicated to supporting companies that enhance quality of life through precision medicine and advanced therapies.

In contrast to funds that focus solely on longevity, this fund prioritizes investments in aging and age-related diseases.

The fund's inaugural investment is in Syngo, a company that specializes in synthetic DNA production for advanced therapies, which enhances production efficiency and supports applications like mRNA vaccines.

Buenavista Equity Partners manages over €1 billion across various investments, while Columbus Venture Partners oversees more than €400 million across four funds, highlighting their strong backgrounds in healthcare investment.